Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$97.02M, compared with -$103.34M a year earlier. Trailing-twelve-month EBITDA was -$473.54M.
Context
- EBITDA amounted to 30.1% of revenue in FY2025, down 20.0 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 18 analysts of -$441.05M (-55.1%) for the fiscal year ending Dec 2026, a slowdown from the +19.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$97.02M+7.9% QoQ
- Last fiscal yearDec 2025
- -$284.31M+19.6% YoY
- LTMSep 2026
- -$473.54M-208.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.1% | +62.5% | +56.4 pp |
| 1 year | +19.6% | -55.1% | -74.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (284.31M) USD
- Year-over-year change
- +19.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (284.31M) | +19.6% |
| FY2024 | 2024-12-31 | (353.72M) | -50.0% |
| FY2023 | 2023-12-31 | (235.87M) | -3.6% |
| FY2022 | 2022-12-31 | (227.76M) | -4290.1% |
| FY2021 | 2021-12-31 | (5.19M) | — |
EBITDA vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's LTM Sep 2026 EBITDA of -$473.54M is the 6th highest of the 9 companies compared; the peer median is -$129.83M.
- Its year-over-year change of -208.3% is the 8th highest of 9, against a peer median of -3.4%.
- EBITDA amounts to 49.3% of revenue for IONS, versus a peer median of 21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.96B | -42.2% | -5.9% | 19.7% | |
| LTM Jun 2026 | $1.15B | +773.6% | — | 24.0% | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$611.26M | +5.0% | — | 85.7% | |
| LTM Sep 2026 | -$81.69B | -10676.6% | +29.2% | 8.0% | |
| Peer median (excluding IONS) | -$129.83M | -3.4% | +11.7% | 21.8% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 810.46M | 587.37M | 787.65M | 705.14M | 944M |
| Cost of Revenue | 10.84M | 14.12M | 9.13M | 11.22M | 16M |
| Gross Profit | 799.61M | 573.25M | 778.51M | 693.92M | 928M |
| Gross Margin | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Research & Development | 643M | 833M | 899.63M | 901.53M | 916M |
| Selling, General & Admin | 170.9M | 150.3M | 232.6M | 267.5M | 394M |
| Operating Expenses | 829.8M | 983.44M | 1.13B | 1.17B | 1.31B |
| Depreciation & Amortization | 19.56M | 22.11M | 22.5M | 21.99M | 22.69M |
| EBITDA | (5.19M) | (227.76M) | (235.87M) | (353.72M) | (284.31M) |
| EBITDA Margin | -0.6% | -38.8% | -29.9% | -50.2% | -30.1% |
| Operating Income | (30.19M) | (410.19M) | (353.73M) | (475.08M) | (382M) |
| Operating Margin | -3.7% | -69.8% | -44.9% | -67.4% | -40.5% |
| Interest Income | 10.04M | 25.33M | 89.04M | 107.02M | 97.77M |
| Interest Expense | 9.35M | 8.12M | 81.46M | 90.45M | 90.54M |
| Other Income / Expenses | 1.04M | 152.21M | 19.77M | 15.01M | 2M |
| Income Before Tax | (29.15M) | (257.99M) | (333.97M) | (460.07M) | (380M) |
| Pre-Tax Margin | -3.6% | -43.9% | -42.4% | -65.2% | -40.3% |
| Income Tax Expense | (551K) | 11.74M | 32.32M | (6.17M) | 1M |
| Net Income | (28.6M) | (269.72M) | (366.29M) | (453.9M) | (381M) |
| Net Margin | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| EPS (Basic) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| EPS (Diluted) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| Weighted Avg Shares | 141.02M | 141.85M | 143M | 149.51M | 160M |
| Weighted Avg Shares (Diluted) | 141.02M | 141.85M | 143.19M | 149.51M | 160M |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.